GLG News by Sutent Prescribers for RCC: Oncologists (US)
Articles with lock require a subscription to GLG News |
Request a free trial
November 6, 2008
GSK to cut sales force , but......
Analysis of: Glaxo Plans 12% Reduction in Its U.S. Drug Sales Force | online.wsj.com
Author: GLG Expert Contributor
GSK to cut sales force , but......Analysis of: Glaxo Plans 12% Reduction in Its U.S. Drug Sales Force | online.wsj.com
Author: GLG Expert Contributor
"As part of the restructuring, the company plans to group its sales staff around specific treatment areas" including oncology, probably
November 6, 2008
Avastin in Glioblastomas: I believe approval will be....
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Avastin in Glioblastomas: I believe approval will be....Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Genetech is seeking FDA approval for use in the most malignant of brain tumors, Glioblastomas.
October 28, 2008The TKI's are building on their success
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
TKI's have been establihed in a small number of refractory solid cancers With slow migration to other venues, we are seeing new applications
October 28, 2008Vaccine for prostate cancer fails
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Recent Cell Genesys vaccine trial for prostate cancer fails
The trial not only shows lack of efficacy, but possible harm from the vaccine arm of the trial
October 27, 2008Hitting the target may reduce the use of targeted cancer drugs or not
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
We are facing an ever increasing expense of treating cancver
The so called targeted drugs are the big price items
The recent discovery of theses drugs have sometimes been out of order with understanding their activity
October 24, 2008
A target may well decrease the market for EGFR inhibitors (Erbitux & Vectibix) in colon cancer (CRC)
Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: GLG Expert Contributor
A target may well decrease the market for EGFR inhibitors (Erbitux & Vectibix) in colon cancer (CRC)Analysis of: Targeting EGFR in Colorectal Cancer | content.nejm.org
Author: GLG Expert Contributor
Measuring mutated K-RAS will show who will NOT respond to ImClone's Erbitux or Amgen's Vectibix. Thus to use either in CRC will not be particularly effective.
October 24, 2008The vaccine approach to cancer has yet to succeed
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Be cautious of vaccine approaches to cancer No cancer has had success with the use of vaccine therapy We are far from figuring out the reason for failure of vaccines to treat cancer
October 23, 2008
Vaccinate smokers?? what is the agenda and the employer of "The Advisory Committee on Immunization Practices."
Analysis of: Panel Calls for Vaccine for Adult Smokers | online.wsj.com
Author: GLG Expert Contributor
Vaccinate smokers?? what is the agenda and the employer of "The Advisory Committee on Immunization Practices."Analysis of: Panel Calls for Vaccine for Adult Smokers | online.wsj.com
Author: GLG Expert Contributor
31 million more doses of Pneumovax yearly in the US??
October 21, 2008
GVAX: Why did it fail? Let me list the possible ways......
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: GLG Expert Contributor
GVAX: Why did it fail? Let me list the possible ways......Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: GLG Expert Contributor
Cell Genesys is basically stopping work on GVAX inview of failure in two trials. The cause of the failure is not readily apparent.
October 20, 2008We must hit the cancer target by genetics or whatever technique
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Targeted therapy for cancer is the new trend
Targeted therapy will allow the use of more expensive drugs to be more practical
We need to focus on hitting a target more than ever
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 506
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008